Kornimate/medical-research-clean huggingface dataset:
multimodal approach to the intrathecal catheter for obstetric accidental dural puncture

Conditions: Spinal Anesthetics Causing Adverse Effects in Therapeutic Use

Summary: accidental dural puncture is an uncommon complication of epidural analgesia and can cause postdural puncture headache.

the aim of this study the effectiveness of a protocol implemented in our department, according to the recommendations of good practice, on the reduction of the use of blood patchs in patients who have had an accidental dural puncture during the implementation of their spinal anesthesia, in order to prevent the use of the blood patch. in addition, intensity of headaches is evaluated.

Eligibility criteria:
inclusion criteria: * patients having an accidental dural puncture during the installation of an epidural anesthesia exclusion criteria: * patients without accidental dural puncture

Keywords: accidental dural puncture epidural blood patch intrathecal catheter postdural puncture headache epidural anesthesia obstetrics
molar intrusion using high pull headgear

Conditions: Anterior Openbite

Summary: this prospective clinical study will evaluate the effect of high pull headgear for molar intrusion, compared with the control group, in adolescent patients with open bite malocclusion. the study sample will consist of 24 patients with anterior open bite divided equally in two groups. the sample will be collected consecutively from patients attending the orthodontic department at damascus university. a modified version of the oba (open bite appliance),introduced by erverdi and usumez, will be applied for all patients. high pull headgears will be used in the first group, while, in the second (control) group, open bite appliances will be used only. the skeletal and dentoalveolar changes occurring after intrusion of posterior teeth will be assessed by using posteroanterior and lateral cephalometric radiographs; pre- and post- treatment changes for each group will be evaluated.

open bite malocclusion is considered one of the most difficult malocclusion to correct in orthodontic treatment because it appears as a result of different etiological factors such as genetic, dental, skeletal, functional, soft tissue, and habits that play roles in its development. different treatment modalities used for the treatment of an anterior open bite. multiloop edgewise archwires, miniscrews, high-pull headgear, and bite blocks have been used for anterior open bite patients, most open bite patients characterized by increased facial height, class ii skeletal pattern, and vertical excess in maxillary posterior teeth. functional appliances, magnets, posterior bite blocks, and high pull headgear are used for posterior teeth intrusion. it is possible to generate intrusive force by using high pull headgear. furthermore, direction of force can be changed according to the center of resistance of the dental units to achieve a better tooth movement control. the intrusion of posterior teeth will lead to decreased lower facial height by a counterclockwise rotation of the mandible; and improve class ii skeletal relationship. this study was the first clinical trial, that compare the effect of high pull headgear for molar intrusion with the control group in adolescent patients.

Eligibility criteria:
inclusion criteria: * patients with skeletal open bite determined by an increased b angle (angle between maxillary plane and mandibular plane), sum of bjork and the mandibular plane angle (angle between sn plane and mandibular plane). * patients between 12 and 18 years old with permanent dentition stage. * negative over bite of more than a mm * class i and class ii skeletal anteroposterior relationship. exclusion criteria: * previous orthodontic treatment. * patients with syndromes, clefts, or craniofacial abnormalities. * class iii skeletal anteroposterior relationship.

Keywords: skeletal openbite molar intrusion high pull headgear
low dose cyclophosphamide treats genital warts

Conditions: Genital Wart

Summary: condylomata acuminata (ca) caused by human papillomavirus (hpv) is a common sexually transmitted disease with half a million new cases diagnosed in the united states per year. recurrence is a major challenge for ca treatment. the investigators have demonstrated that foxp3+ regulatory t (treg) cells mediate the immunosuppression in large genital warts. and low-dose cyclophosphamide (cy), a conventional chemotherapy drug, has been reported to selectively deplete treg cells in cancer patients. therefore, the investigators hypothesized that low-dose cy can be used to treat genital warts. in this study, 104 ca patients have been recruited for clinical trial with a 1:2 randomization. among them, 64 patients received low-dose cyclophosphamide and 32 received placebo. in 8 extra patients, high-dose cyclophosphamide was given.

patients were first treated with co2 laser therapy, and then treated with low-dose cy, orally 50 mg per day for 7 days.the ca recurrence were observed.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of large genital warts exclusion criteria: * hpv type 6 or 11 was detected negatively by pcr method.
safety and efficacy of sh t00660aa in treatment of endometriosis

Conditions: Endometriosis

Summary: the purpose of this study is to demonstrate safety and efficacy of sh t00660aa for the treatment of endometriosis

the study has previously been posted by schering ag, germany. schering ag, germany has been renamed to bayer schering pharma ag, germany.bayer schering pharma ag, germany is the sponsor of the trial.

Eligibility criteria:
inclusion criteria: * female patients with endometriosis-associated pelvic pain exclusion criteria: * pregnant or lactating women * history or suspicion of hormone dependent tumor * therapy resistant endometriosis or need for primary surgical treatment * any other conditions which forbid the participation
effects of barley green in patients with hyperuricemia

Conditions: Dietary Supplement

Summary: this experiment evaluates the effect of barley green in patients with hyperuricemia ， and explores the effect of barley green on metabolic indexes such as uric acid, blood lipids, blood glucose, free fatty acids。130 adult participants , age 18 to 65 years, will be randomized into one of the two arms. arm a (control group) will receive dietary guidance. arm b will receive dietary guidance and barley green.


Eligibility criteria:
inclusion criteria: * age 18-65 years old those who are willing to accept assessment and sign informed consent. * under the normal purine diet, two fasting blood uric acid levels on different days: 420umol/l \<blood uric acid \<540 umol/l (male), 360 umol/l \<blood uric acid \<540 umol/l (female) exclusion criteria: * patients currently receiving treatment for hyperuricemia； * suffering from diseases that affect the digestion and absorption(such as chronic diarrhea, constipation, severe gastrointestinal inflammation, active gastrointestinal ulcers, after gastrointestinal resection, cholecystitis/cholecystectomy, etc.)； * suffering from cardiovascular and cerebrovascular diseases, grade 3 hypertension, chronic hepatitis, malignant tumors, anemia, mental illness and memory disorders, epilepsy and other diseases; * at the same time receive other functional food nutrition support (plant active substances, health food); * patients with abnormal liver function (alanine aminotransferase or/and aspartate aminotransferase exceeds 3 times the upper limit of normal value); patients with abnormal renal function (serum creatinine exceeds the upper limit of normal value)； * suffering from infectious diseases such as active tuberculosis and aids; * people who are severely allergic to the ingredients of research； * during pregnancy or lactation; * patients with physical disabilities and clinicians think it is not suitable to participate in the study (for example, suffering from serious diseases not included in the discharge criteria)； * gouty arthritis attack ≥ 2 times; * one episode of gouty arthritis with blood uric acid \>480 umol/l, or any of the following: age \<40 years old, evidence of gout stone or urate deposition in the joint cavity, uric acid nephrolithiasis or renal impairment (gfr≤89ml/(min·1.73m2)), hypertension, impaired glucose tolerance or diabetes, dyslipidemia, obesity, coronary heart disease, stroke, cardiac insufficiency; * blood uric acid\>480 umol/l combined with any of the following: uric acid nephrolithiasis or renal impairment (gfr≤89ml/(min·1.73m2)), hypertension, impaired glucose tolerance or diabetes, dyslipidemia, obesity, coronary heart disease, stroke, heart failure.
gene modulation of nlrp3, il-1β and tnf-α in peripheral blood of patients with exogenous obesity treated with berberine

Conditions: Obesity; Overweight; Berberine

Summary: the patients will be invited to participate in a research study aimed at determining the gene modulation of nlrp3, il-1β and tnfα in peripheral blood of patients with exogenous obesity treated with berberine.

the study will take 6 months in total, in this study will participate patients with exogenous obesity, which is defined as an abnormal accumulation of fat that can be detrimental to health. after the evaluation it will be determined if you meet the section criteria to be able to participate in the study. the patients will be randomly assigned to a group which may be: group i. the investigator will give a nutritional plan according to your caloric requirements for lifestyle change and the patients will be scheduled biweekly for 3 months to assess your weight, height, body mass index and percentages of fat or muscle. group 2. the investigator will be given a nutritional plan and controlled moderate aerobic exercise that will consist of a goal of 10,000 steps or 150 minutes per week. the patient will be given a lifestyle change plan in accordance with their nutritional requirements. group 3. the investigator will give a nutritional plan, moderate aerobic exercise with a goal of 10,000 steps or 150 min per week; and the phytopharmaceutical berberine will take 3 tablets every 8 hours for 3 months. biweekly sessions will be carried out for 3 months, then monthly for 6 months; blood samples will be taken at the beginning of the study, that is, after the informed consent, at 3 and 6 months.

Eligibility criteria:
inclusion criteria: * • patients with bmi ≥ 30kg/m2 * with risk factors for type 2 diabetes (history of diabetic parents or siblings, sedentary habits) * fasting blood glucose ≤ 126 mg/dl or glycosylated hemoglobin \< 6.5% * controlled arterial hypertension * \>18 years of age * accept and sign the informed consent exclusion criteria: * • pregnancy patients * diabetics patients * presenting any serious adverse effect * patients who decide to withdraw from the protocol

Keywords: obesity overweight berberine
biomarkers for post-transplant lymphoproliferative disorders in children

Conditions: Heart Transplant; Small Intestine Transplant; Kidney Transplant; Liver Transplant; EBV-Related PTLD; PTLDs

Summary: solid organ transplantation is an important therapeutic option for children with a variety of end stage diseases. however, the same immunosuppressive medications that are required to prevent the child's immune system from attacking and rejecting the transplanted organ can predispose these individuals to developing a very serious cancer that is linked to epstein-barr virus (ebv).

ebv-associated post-transplant lymphoproliferative disease (ptld) is the most common malignancy in children after transplant. diagnosis and effective treatment of the ebv-associated cancer is hampered by our inability to determine which children are at risk of developing these cancers and to detect the cancer at an early stage. in this study, we plan to test new "biomarkers" in the blood of children that will tell us very early on if the child is at risk of developing the ebv-associated cancer or if the cancer is present. these studies provide new opportunities for detection, diagnosis, and treatment of children with ebv-associated, post-transplant cancer.

Eligibility criteria:
inclusion criteria: * subject and/or parent or legal guardian must be able to understand and provide informed consent/assent; * candidate for or recipient of: heart, liver, heart with liver, small intestine, liver with small intestine, or kidney; and * subject enrolled within 3 years of transplant. exclusion criteria: * previous diagnosis of ptld; * transplant recipients of lung alone, or in combination with an eligible organ type; * pancreas transplantation with the exception of 'en bloc' transplant in combined liver and small intestine multivisceral transplantation; * any combination other than listed in inclusion criteria; * history of any previous solid organ, stem cell, or bone marrow transplantation; * inability or unwillingness of the legal guardian and/or the subject to comply with the study protocol.

Keywords: biomarkers post-transplant lymphoproliferative disorders (ptlds)
hyperbaric oxygen therapy attenuates central sensitization induced by a thermal injury in human volunteers (hbo)

Conditions: Pain; Inflammation; Hyperalgesia

Summary: the hypothesis of this investigation is to observe if hbo have an anti-inflammatory effect in humans induced by tonic heat stimulation. it has been shown in animal studies with rats that hbo could reduce the paw edema induced by carrageenan as an inflammatory agent. the authors are not aware of similar studies in human subjects investigating this effect of hbo. aim: to investigate the anti-inflammatory effect of hbo by reducing the hyperalgesia induced by heat stimulation in healthy subjects and promote future research and understanding of the anti-inflammatory processes in humans. the primary endpoint is a reduced area of secondary hyperalgesia after hbo.


Eligibility criteria:
inclusion criteria: * age \> 18 yr approved physical health examination healthy male exclusion criteria: * arterial hypertension chronic pain claustrophobic tendency history of substance abuse impaired cognitive abilities inability to participate in quantitative sensory testing incomplete understanding of danish neurological deficits previous barotrauma or pneumothorax previous head trauma unable to equilibrate pressure in middle ear and/or sinuses

Keywords: pain inflammation hyperalgesia burn injury hyperbaric oxygen
vitamin d in diabetic children

Conditions: Vitamin D Deficiency

Summary: vitamin d is so-called "sunshine vitamin",it is synthesized in the skin during exposure to the ultraviolet rays in sunlight so it has been suggested that ∼ 5-30 minutes of sun exposure between 10:00 a.m. and 3:00 p.m. at least twice per week on the skin of the face, arms, back, or legs (without sunscreen) is usually adequate for vitamin d synthesis. vitamin d is also found in plants (mainly mushrooms and yeast) and in a few foods such as fatty fish. vitamin d supplement is recommended in all infants until enough formula, milk, or other food sources are ingested to sufficiently provide 400 iu/day to prevent vitamin d deficiency. type 1 diabetes is an autoimmune disease, and the self immune system plays a central role in the destruction of the beta cell of pancrease.


Eligibility criteria:
inclusion criteria: * age (5 years - 15 years ). * type 1 diabetes patients. exclusion criteria: * patients aged more than 15 years, less than 2 years. * type 2 diabetes. * neonatal diabetes. * patients with any complications from diabetes.
measurement of bladder function change in patients with svms before and after surgical intervention

Conditions: Spinal Vascular Disorder Nos; Neurogenic Bladder Dysfunction Nos

Summary: the investigators goal is to create a better understanding of patient with svms reported outcomes for bladder management strategies before and after surgery.

spinal vascular malformations (svms) are complex neurosurgical lesions and account for 3%-4% of all intradural spinal cord mass lesions, which can influence the function of bladder. however, no study show the relationship of the svms and bladder function. the investigators goal is to create a better understanding of patient reported outcomes for bladder management strategies before and after surgery.

Eligibility criteria:
inclusion criteria: - patient diagnosed with spinal vascular diseases including intradural arteriovenous malformation, intradural arteriovenous fistula, dural arteriovenous fistula, extradural arteriovenous malformation, paravertebral arteriovenous malformation, paravertebral arteriovenous fistula, cobbs' syndrome, other spinal arteriovenous metameric syndromes involve the spinal cord. patient not received surgical or interventional treatment before patient with normal cardiac, renal and hepatic function patient capable of understanding the content of the patient information / informed consent form patient willing and able to participate in the registry exclusion criteria: - patient received surgical treatment or interventional treatment before patient is pregnant patient allergic to iodine patient unable to complete follow-up patient with cerebral lesions patient with other spinal lesions patient with cardiac, renal or hepatic dysfunction

Keywords: spinal vascular malformations bladder surgical intervention urodynamics
smartguard use in real life : a longitudinal study in patients with type 1 diabetes

Conditions: Type 1 Diabetes Mellitus Maturity Onset

Summary: the reference treatment of the type 1 diabetes is intensified insulin therapy by insulin pump. the cgm (continuous glucose monitoring) is a technology available for a decade, which allows the continuous measure of interstitial glucose rate. the results are available in real time to the user, who can so use them to optimize the adjustment of its treatment by insulin pump. since a few years, several research programs aim for finalizing an automated system using the data of real time interstitial glucose to adjust automatically, via an algorithm, the release of insulin by the pump. this type of closed-loop system is for the moment only experimental, not still widely available in routine. on the other hand, rudimentary regulation systems partially automated already exist and can be used in common clinical practice. one of these systems, smartguard ®, allows this type of regulation to decrease the hypoglycemic risk of the patients treated by insulin pump. it is indeed a hypo minimizer which interrupts the basal output when the algorithm embarked on the pump determines thanks to the cgm data what a hypoglycemia risks to occur in the 30 minutes. the efficiency of this system to reduce hypoglycemias was proved by several studies in pediatric and adult populations of subjects with dt1 (diabetes care on 2015; 38:1197-1204. j diabetes sci technol. 2016 may 20. pii: 1932296816645119). however, to date, there are no published data concerning the method of use of this system (sensor et pump initial configuration; patient education), nor the evolution of the sensor and pump parameters during the use. the aim of this observationnelle study is to collect the data of efficiency, safety and use of the system smartguard ® in common clinical practice in an adult population of subjects dt1.


Eligibility criteria:
inclusion criteria: * type 1 diabetes ≥ 1 year * csii ≥ 6 months * previous education to flexible insulin therapy * patient willing to use sensors and smartguard option for 1 year * a1c ≥ 7.5% and/or severe hypoglycemia ≥ 2 episodes during the last 6 month and/or recurrent hypoglycemia and/or hypoglycemia unawareness and/or brittle diabetes exclusion criteria: * no access to a computer and/or to the web making it impossible to follow patients through telemedicine

Keywords: insulin pump continuous glucose monitoring sensor predictive low glucose suspend
prophylactic antibiotic after perineal tear

Conditions: Puerperal Infection

Summary: current world health organization guidelines recommend routine antibiotic prophylaxis for women with perineal tear 3rd and 4th degree but not for 2nd degree because of insufficient evidence of effectiveness. the investigators aimed to investigate whether antibiotic prophylaxis prevented maternal infection after the first and second perineal tear after vaginal birth.

the patpet trial is a randomized, controlled trial done at tertiary hospital obstetric units in israel. women who had first and second-degree tear (or after episiotomy) after delivery at 37 weeks or greater gestation, with no indication for ongoing prescription of antibiotics in the post-partum period and no contraindications to prophylactic cefamezin (cefazolin), were randomly assigned (1:1) to receive a single intravenous dose of prophylactic antibiotic or not.

Eligibility criteria:
inclusion criteria: * age 18-45 * perineal tear 2nd and 1st degree( episiotomy) exclusion criteria: * 3rd and 4 th degree perineal tear * antibiotic indication during delivery * cesarian section delivery
a study to compare the nexgen lps and lps-flex knee implants

Conditions: Total Knee Arthroplasty; Osteoarthritis

Summary: the purpose of this study is to test for significant differences in functional outcomes obtained by using a nexgen lps versus a nexgen lps-flex knee implant. specifically, it is predicted that an increase in postoperative range of motion will be experienced by patients treated with the nexgen lps-flex knee implant.

this study will compare the clinical results of the nexgen lps femoral component with the higher flexion potential of the nexgen lps-flex femoral component in all patients with degenerative joint disease that require total knee arthroplasty. the primary variable of interest is postoperative range of motion achieved with the two devices, which are implanted with slightly different surgical techniques in patients who may also be subjected to different rehabilitation programs depending on the device they are assigned.

Eligibility criteria:
inclusion criteria: * age, 21-80 years * sex, males and females will be included * bmi less than or equal to 39 and calf-thigh less than or equal to 90 degrees * stable health, the patient would be able to undergo surgery and participate in the follow-up program based on physical examination and medical history. * patient is willing and able to cooperate in follow-up therapy. * patient exhibits preoperative radiographic evidence of joint degeneration consistent with tka that cannot be treated in non-operative fashion. * patient has stable and functional collateral ligaments. * patient has potential to perform higher than average range of motion activities. * operative side range of motion flexion greater than or equal to 90 degrees. * severe knee pain and disability due to degenerative joint disease. * patient or patient's legal representative has signed the informed consent form. exclusion criteria: * previous history of infection in the affected joint. * previously failed knee endoprosthesis of any kind. * charcot joint disease or other severe neurosensory deficits. * previous patellectomy. * patient is skeletally immature. * grossly insufficient femoral or tibial bone stock. * patient is pregnant. * varus or valgus deformity greater than 20 degrees. * fixed flexion deformity greater than 15 degrees. * previous high tibial osteotomy. * previous femoral osteotomy. * patient is a poor compliance risk - currently treated for ethanol or drug abuse, physical or mental handicap, etc. * loss of musculature or absence of musculoligamentous supporting structures required for adequate soft tissue balance.

Keywords: total knee arthroplasty osteoarthritis knee